I-Mab
I-Mab (IMAB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMAB · as of Jun 8, 2026
Key Statistics
Explore I-Mab Data
imab stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
The IMAB analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $7.75, representing +169.10% upside from the current price of $2.88.
Competitors & Peers
imab competitorsIMAB
ALT
ANNX
AURA
DMAC
DRTSStock Performance
Full HistoryAbout I-Mab
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical med…
what is i-mab · imab stock overview · i-mab company profile · who is i-mab ceo · imab NASDAQ · i-mab headquarters · i-mab business segments
About Stock Overview & Key Data
I-Mab (IMAB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 17, 2020. As of the latest trading session, IMAB stock price is $2.88, with a market capitalization of $542.0M. The stock has returned +242.32% over the past 12 months and +0.00% year-to-date.
According to 5 Wall Street analysts, the consensus rating for I-Mab stock is Buy, with an average 12-month price target of $7.75. In fiscal year 2024, I-Mab reported revenue of — and net income of -$22.2M. For detailed data — including I-Mab revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, I-Mab (IMAB) stock price is $2.88. The stock is traded on NASDAQ under the ticker symbol IMAB. The 52-week range is $0.59 – $6.79.